Vancouver, B.C., May 4, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that the Company has acquired an additional 23% of the Sublime Culture Inc, Quebec production facility from CannaTechnology (the “seller”), bringing total ownership of the late stage ACMPR applicant up to 74%. The Company also announces it has retained Cannabis Compliance Inc., the country’s leading experts in cannabis regulatory compliance, as the consultant on file for both Quebec projects and all other Health Canada licenses with respect to cannabis production, sale, and R&D.

“We are thrilled to obtain an additional 23% of the ACMPR Sublime Culture facility, bringing MYM ownership up to 74%,” said Rob Gietl, CEO of MYM. “Construction on phase one of the facility is now complete and the ACMPR application is currently with Health Canada under final review.”

Immediately issued to the seller is 350,000 MYM common shares and 100,000 transferable warrants. Each warrant will entitle the holder to purchase one (1) MYM common share at an exercise price of $2.04 per share, being equal to the closing price of the MYM common shares on the Canadian Securities Exchange immediately prior to the date of this Agreement plus 20%. The warrants will become exercisable six (6) months after the date of issuance and will expire two (2) years after the date of issuance. Upon ACMPR Sublime Culture acquiring a cultivation license for the facility, MYM will issue the seller an additional 350,000 MYM common shares.

Moving forward, MYM has retained the services of Cannabis Compliance Inc. to consult the Company on regulatory compliance and due diligence for all its ACMPR projects in Canada. “Joining forces with Cannabis Compliance as our consultant on file for all medicinal cannabis projects is the necessary solution to advance our applications in a timely manner,” said Gietl. “Cannabis Compliance has an amazing track record in leading ACMPR applicants to the finish line. With their guidance, MYM intends on progressing full steam ahead into what will prove to be a very exciting 2018.”

About MYM Nutraceuticals Inc.MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).